Saturday 17 October 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
819.14
27.13
−3.21%
Follow ARGX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 4 | 2 | 4 | 2 | 4 | 4 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.69 | 39.97 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 143.06 | 26.15 | 45.65 | 17.17 | 16.35 | 12.13 |
Altman Z-Score |
— | 32.38 | 40.99 | 9.02 | 12.87 | 34.00 | 37.95 | 29.53 | 32.17 | 24.36 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 20.35 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 87.59 |
Altman Z″-Score (non-manufacturers) |
1.66 | 18.67 | 18.24 | 6.84 | 5.05 | 11.16 | 10.65 | 12.66 | 11.80 | 10.58 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (1.45) | (2.72) | 1.17 | (3.69) | 4.27 | 4.63 | (1.01) | (0.33) | (1.51) |
P/B ratio |
0.00 | 0.00 | 0.00 | 5.31 | 8.31 | 7.06 | 7.22 | 5.32 | 6.70 | 7.04 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 5.52 | 9.23 | 7.57 | 7.70 | 5.48 | 6.92 | 7.31 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 122.56 | 24.20 | 43.86 | 15.56 | 15.68 | 11.31 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.61 |
EV/Operating CF |
0.00 | 0.00 | 2.16 | 18.93 | 3,835.64 | (13.39) | (8.92) | (9.57) | (38.67) | 57.23 |
EV/FCF |
0.00 | 0.00 | 2.13 | 19.15 | (13,199.23) | (13.30) | (8.89) | (8.05) | (30.68) | 81.66 |
Quick Ratio |
2.19 | 7.54 | 7.14 | 2.25 | 3.73 | 4.56 | 3.57 | 6.02 | 3.60 | 3.90 |
Current Ratio |
2.40 | 14.13 | 14.29 | 8.58 | 6.26 | 8.44 | 9.18 | 9.75 | 7.29 | 5.23 |
Net Debt/EBITDA |
4.30 | 8.56 | 3.48 | 1.88 | 2.57 | 3.89 | 1.30 | 6.53 | 363.46 | (3.23) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.07 | 0.17 | 0.06 | 0.08 | 0.03 | 0.21 | 0.15 | 0.33 | 0.42 | 0.57 |
Operating CF/Net income |
(0.50) | 1.30 | 0.81 | (0.83) | 0.65 | 1.49 | 1.22 | 1.42 | (0.10) | 0.53 |
Capex/Depreciation |
(2.58) | (0.81) | (1.39) | (19.27) | (1.31) | (20.70) | (0.99) | (0.39) | (3.90) | (3.97) |
Interest Coverage |
— | (57.37) | (22.77) | (1,439.74) | (318.20) | (76.18) | (184.42) | (469.15) | (8.79) | 258.16 |
| (9.74%) | (13.80%) | (15.35%) | (20.14%) | (42.69%) | (19.40%) | (26.54%) | (8.54%) | 17.36% | 20.15% | |
| (8.39%) | (11.83%) | (14.28%) | (15.95%) | (31.33%) | (15.92%) | (23.71%) | (7.69%) | 15.51% | 17.36% | |
ROIC |
0.00% | (9.41%) | (20.01%) | (15.51%) | (65.28%) | (18.17%) | (22.37%) | (12.97%) | (0.34%) | 17.19% |
Return on Tangible Assets |
(35.53%) | (8.22%) | (12.50%) | (13.34%) | (34.97%) | (18.08%) | (28.52%) | (7.92%) | 19.57% | 22.96% |
Average Days of Receivables |
45.39 | 26.54 | 39.79 | 125.41 | 41.84 | 25.86 | 227.29 | 143.65 | 147.34 | 142.38 |
Research and Development Expense of Revenue |
183.98% | 125.41% | 286.03% | 239.35% | 571.37% | 107.62% | 148.98% | 67.75% | 43.67% | 32.11% |
Selling, General and Administrative Expense of Revenue |
40.88% | 30.17% | 93.98% | 78.19% | 264.43% | 57.03% | 106.03% | 56.12% | 46.86% | 32.18% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.03 | 0.07 | 0.06 | 0.06 | 0.03 | 0.03 | 0.03 |
Share Based Compensation of Revenue |
16.61% | 10.35% | 65.63% | 47.89% | 149.33% | 33.25% | 35.27% | 18.36% | 10.44% | 5.84% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.18 | 0.10 | 0.12 | 0.12 | 0.17 | 0.11 | 0.11 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 168.64 | 237.82 |
Earnings Yield |
(5.22%) | (4.03%) | (1.63%) | (3.93%) | (6.52%) | (2.52%) | (3.51%) | (1.35%) | 2.24% | 2.50% |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 4.91% | (0.01%) | (6.96%) | (10.80%) | (11.25%) | (3.13%) | 1.14% |
Revenue per Share |
1.01 | 1.89 | 1.03 | 2.40 | 1.43 | 10.56 | 8.19 | 22.19 | 37.62 | 69.31 |
Operating CF per Share |
0.62 | (1.68) | (1.90) | 3.90 | (8.77) | (11.88) | (15.87) | (7.35) | (1.38) | 11.18 |
Capex per Share |
(0.05) | (0.02) | (0.02) | (1.21) | (0.11) | (2.38) | (1.91) | (0.77) | (1.14) | (1.82) |
Free Cash Flow per Share |
0.57 | (1.69) | (1.93) | 2.69 | (8.89) | (14.26) | (17.78) | (8.12) | (2.52) | 9.36 |
Cash per Share |
5.33 | 8.84 | 9.99 | 9.61 | 26.80 | 26.13 | 14.72 | 35.84 | 25.06 | 56.96 |
Shareholders Equity per Share |
3.73 | 15.84 | 19.03 | 30.47 | 36.87 | 49.62 | 51.74 | 71.67 | 91.86 | 119.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.73 | 15.84 | 19.03 | 30.47 | 36.87 | 49.62 | 51.74 | 71.67 | 91.86 | 119.47 |
Free Cash Flow |
10.78 | (41.70) | (64.39) | 103.98 | (403.60) | (728.25) | (966.63) | (464.14) | (151.05) | 573.51 |
Working Capital |
65.73 | 385.27 | 628.75 | 1,358.85 | 1,728.51 | 2,241.73 | 2,471.92 | 3,700.74 | 4,213.19 | 5,578.92 |
Capital Expenditures |
(0.95) | (0.40) | (0.81) | (46.76) | (5.14) | (121.43) | (103.82) | (43.81) | (68.30) | (111.68) |
Net Current Asset Value |
65.73 | 385.24 | 628.74 | 1,109.50 | 1,451.65 | 2,226.92 | 2,453.64 | 3,678.79 | 4,178.86 | 5,539.50 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.61 |
Capex to Sales |
0.05 | 0.01 | 0.02 | 0.51 | 0.08 | 0.23 | 0.23 | 0.03 | 0.03 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.91 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.44 | 0.64 | 0.60 | 0.27 | 0.34 | 0.37 | 6.43 | 4.91 | 0.40 | 0.58 |
Cash ROIC |
6.32% | (6.86%) | (6.64%) | 6.72% | (13.96%) | (18.82%) | (26.74%) | (7.55%) | (2.16%) | 5.30% |
Accounts Receivable Turnover |
6.35 | 16.22 | 9.65 | 5.20 | 3.31 | 23.63 | 2.82 | 3.27 | 3.20 | 3.31 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.33 | 0.43 | 0.47 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.17 | 0.44 | 0.63 | 1.02 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,666.98 | 1,282.43 | 1,043.81 | 1,026.28 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 2,832.01 | 961.94 | 653.97 | 383.52 |
Average Receivables |
2.99 | 2.88 | 3.58 | 17.77 | 19.61 | 22.83 | 157.75 | 388.27 | 704.18 | 1,283.08 |
Average Payables |
9.15 | 15.38 | 30.53 | 69.66 | 185.36 | 284.30 | 294.55 | 354.85 | 532.00 | 958.57 |
Average Inventory |
— | — | — | — | 67.51 | 67.14 | 168.71 | 269.45 | 358.89 | 440.38 |
Average Assets |
282.02 | 268.14 | 551.20 | 1,144.25 | 1,942.37 | 2,564.84 | 2,992.27 | 3,838.36 | 5,372.49 | 7,442.61 |
Average Common Equity |
242.90 | 230.00 | 512.86 | 906.34 | 1,425.44 | 2,104.14 | 2,673.96 | 3,455.60 | 4,797.90 | 6,410.69 |
Columns are period end dates